BRAF Mutation is Associated with Early Stage Disease and Improved Outcome in Patients with Low-Grade Serous Ovarian Cancer

BACKGROUND: Low-grade serous (LGS) ovarian cancer (OC) is a chemoresistant disease that accounts for 10% of serous ovarian cancers. Prior studies have reported that 28–35% of serous borderline (SB)/LGS ovarian tumors harbor a BRAF mutation, suggesting that BRAF inhibitors may be a rational therapeut...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Grisham, Rachel N., Iyer, Gopa, Garg, Karuna, Delair, Deborah, Hyman, David M., Zhou, Qin, Iasonos, Alexia, Berger, Michael F., Dao, Fanny, Spriggs, David R., Levine, Douglas A., Aghajanian, Carol, Solit, David B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3961140/
https://ncbi.nlm.nih.gov/pubmed/22930283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27782
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados